The Renaissance of Platinum-Based Chemotherapy for Metastatic Breast Cancer

References

• Quinn M, Babb P, Brock A, Kirby L, Jones J. Breast can-cer trends in England and Wales 1950-1999. London: the Sta- tionery Office, 2001; 40-45.
   Google Scholar
• Martin M. “Platinum compounds in the treatment of ad-vanced breast cancer”. Clin. Breast Cancer 2001; 190–208.
   PubMedGoogle Scholar
• Smith 1E, Talbot DC. “Cisplatin and its analogues in the treatment of advanced breast cancer: a review” Br. J. Cancer 1992; 787–793.
   Google Scholar
• DiXit M, Yang JL, Poirier MC et al. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst 1997; (89): 365-373.
   Google Scholar
• Pegram MD, Lopez A, Konecny G, et al. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000 (suppl 11);(27): 21-25.
   Google Scholar
• Reed E. Cisplatin and analogs. In: Chabner BA, Longo DL editors. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia: Lippincott Wiliams and Wilkins 2001: 447-465.
   Google Scholar
• Go RS, Adjei AA. Review of the comparative pharmacol-ogy and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; (17): 409-422.
   Google Scholar
• Pascoe JM, Roberts JJ. Interactions between mammalian cell DNA and inorganic platinum compounds : 11. Interstrand cross-linking of isolated and cellular DNA by platinum (IV) com-pounds. Biochem Pharmacol 1974; (23): 1345-1357.
   Google Scholar
• Canetta R, Goodlow J, Smaldone L, et al. Pharmacologic characteristics of carboplatin: clinical experience. In: Bunn PA, Canetta R, Ozols RF et al., editors. Current Perspectives and fu-ture directions. Philadelphia: WB Saunders 1990: 19-38.
   Google Scholar
• Raymond E, Faivre S, Woynarowsky JM, Chaney SG. Ox-aliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; (25): 4-12.
   Google Scholar
• Brienza S, Gastiaburu J, Cvitkovic E, et al. Clinical char-acteristics and reversibility of neurological signs after long-term oxaliplatin (L-OHP) therapy. Ann Oncol 1994 (suppl 5):128 (abstr 225).
   Google Scholar
• Extra JM, Espie M, CaIvo F, Ferme C, Mignot L, Martyn M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; (25): 299-303.
   Google Scholar
• Kolaric K, Roth A. Phase II clinical trial of cis-dichlorodi-ammine platinum (cis-DDP) for antitumorigenic activity in previ-ously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983; (11): 108-112.
   Google Scholar
• Sledge Jr GW, Loehrer PJ, Sr BJ, Roth LH. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988;(6): 1811–1814.
   Google Scholar
• Mechl Z, Sopkova B. CAP (cyclophosphamide, adri-amycin, cisplatinum) in the treatment of advanced breast cancer. Neoplasma 1984; (31): 431-435.
   Google Scholar
• Bajorin D, Bosl GJ, Fein R. Phase I trial of escalating doses of cisplatin in hypertonic saline. J Clin Oncol 1987; (5): 1589-1593.
   Google Scholar
• Foresterie AA, Hakes TB, Wittes JT, Wittes RE. Cisplatin in the treatment of metastatic breast carcinoma: a prospective randomized trial of two dosage schedules. Am J Clin Oncol 1982; (5): 243-247.
   Google Scholar
• Martino S, Samal BA, Singhakowinta A, et al. A phase II study of cis- diamminochloroplatinum II for advanced breast can-cer. Two dose schedules. J Cancer Res Clin Oncol 1984; (108): 354-356.
   Google Scholar
• Ostrow S, Egorin M, Aisner J, Bachur N, Wiernik PH. High-dose cis-diamminochloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and thera-peutic efficacy. Cancer Clin Trials 1980; (3): 23-27.
   Google Scholar
• Ramnath N, Lo Russo P, Simon M, Martino S. Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer. Am J Clin Oncol 1997; (20): 368-372.
   Google Scholar
• Yap HY, Salem P, Hortobagy GN, et al. Phase II study of cis-diamminochloroplatinum (II) in advanced breast cancer. Can-cer Treat Rep 1978; (62): 405-408.
   Google Scholar
• Crown J. Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist 2001; (6): 17-21.
   Google Scholar
• Schabel Jr FM, Trader MW, Laster Jr WR, Corbett TH, Griswold Jr DP. cis- Dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; (63): 1459-1473.
   Google Scholar
• Durand RE, Goldie JH. Interaction of etoposide and cis-platin in an in vitro tumor model. Cancer Treat Rep 1987; (71): 673-679.
   Google Scholar
• Remick SC, Chmura M, Bromberg C, Sporn J, Healey B, Hilstro J. Concurrent 72-h continuous infusion of etoposide and cisplatin in metastatic breast cancer. Am J Clin Oncol. 1996;125–131.
   PubMed Web of Science ®Google Scholar
• Cocconi G, Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1991;664–669.
   PubMed Web of Science ®Google Scholar
• Lluch A, Azagra P, Cervantes A, et al. Phase II trial of cis-platin and etoposide as first-line therapy in metastatic breast car-cinoma. Oncology 1994;352–355.
   PubMed Web of Science ®Google Scholar
• Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fos-ser V, Tonato M. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carci-noma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999;1599–1605.
   Google Scholar
• Tinsley R, Fuks J, Korzun A. Cisplatin and etoposide for advanced breast cancer. Proc Am Soc Clin Oncol 1986;287.
   Google Scholar
• Krook JE, Loprinzi CL, Schaid DJ, Kardinal CG, Mailliard JA, Pfeifle DM. Evaluation of the continuous infusion of etopo-side plus cisplatin in metastatic breast cancer. A collaborative North Central Cancer Treatment Group/Mayo Clinic phase II study. Cancer 1990;418–421.
   Google Scholar
• Fried G, Stein ME, Haim N. Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: a phase II study. Med Pediatr Oncol 2000;10–13.
   PubMedGoogle Scholar
• Ceci G, Bisagni G, Cocconi G, Rodino C, Belsanti V, Bertusi M. Cisplatin and VP16 in metastatic breast carcinoma as a third-line chemotherapy: a randomized study comparing low versus high doses of cisplatin. Tumori 1995;241–244.
   PubMed Web of Science ®Google Scholar
• Icli F, Akbulut H, Uner A, Bulent Y, Altinbas M, Baltali E. Paclitaxel (T) vs cisplatin+VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: a phase III randomized study, Turkish Oncology Group. Ann Oncol 2002; 47.
   PubMedGoogle Scholar
• Cox EB, Burton GV, Olsen GA, Vugrin D. Cisplatin and etoposide: an effective treatment for refractory breast carcinoma. Am J Clin Oncol 1989;53–56.
   PubMed Web of Science ®Google Scholar
• Icli F, Gunel N, Dincol D, Karaoguz H, Demirkazik A. Cis-platin plus VP-16 combination chemotherapy in advanced re-fractory breast cancer. J Surg Oncol 1992;251–253.
   PubMed Web of Science ®Google Scholar
• Bromberg C, Remick S, Harper G. Concurrent 72 h con-tiuous infusion of etoposide and cisplatin in metastatic breast can-cer. Proc Am Soc Clin Oncol 1991; 49.
   PubMedGoogle Scholar
• Levitt NC, Dobbs NA, Braybrooke J. A phase 1/II study of cisplatin and pharmacokinetically guided infusional etoposide phosphate in anthracycline resistant breast cancer. Proc Am Soc Clin Oncol 1999;112.
   Google Scholar
• Cocconi G, Tonato M, Di Costanzo F, et al. Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Re-search (G.O.I.R.C). Eur J Cancer Clin Oncol 1986;761–764.
   Google Scholar
• Athanassiades P, Bacoyiannes H, Kontoyiannes D. Etopo-side (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in ad-vanced breast carcinoma resistant to previous chemotherapy. Chemioterapia 1986;125–127.
   PubMedGoogle Scholar
• Giaccone G, Donadio M, Ferrati P, Calciati A. Cisplatin and etoposide in chemotherapy-refractory advanced breast can-cer. Tumori 1988;191–193.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Neuberg D, Glick JH, et al. Phase 11 trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1997;1880–1884.
   Google Scholar
• McCaskill-Stevens W, Ansari R, Fisher W. Phase II study of biweekly cisplatin (C) and paclitaxel (P) in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1996; 120.
   Google Scholar
• Gelmon KA, O'Reilly SE, Tolcher AW, Campbell C, Bryce C, Ragaz J. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996;1185-1191.
   Google Scholar
• ” Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neu-rotoxicity. J Clin Oncol 1996;1993-1999.
   Google Scholar
• Browne MJ, Kennedy T, Cummings F. Phase II study of sequential taxol and cisplatin for the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1995;136.
   Google Scholar
• Ezzat A, Raja MA, Berry J, et al. A phase II trial of circa-dian-timed paclitaxel and cisplatin therapy in metastatic breast cancer. Ann Oncol 1997; 663–667.
   PubMed Web of Science ®Google Scholar
• Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. Breast Can-cer Res. Treat. 1998;13–26.
   Google Scholar
• Gainford C, O'Leary M, El-Fiki T. Phase I trial of docetaxel (T) and cisplatin (P) as first-line chemotherapy for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000; 113a.
   Google Scholar
• Crown J, Fumoleau P, Kerbrat P. Phase I trial of docetaxel (D) with cisplatin (P) as first-line chemotherapy of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1997; 233a.
   Google Scholar
• Llombart-Cussac A, Spielmann M, Dohollou N. Cisplatin-taxotere phase I/II trial in patients with anthracycline-resistant advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1997;551.
   Google Scholar
• Pescia V, Bordenave HR, Foglia S. Taxotere (T) and cis-platin (P) in anthracycline-pretreated advanced breast cancer (ABC): preliminary results. Proc Am Soc Clin Oncol 2000;117a.
   Google Scholar
• Antoine E, Meric JB, Coeffic D. Anthracycline-primary resistant breast cancer: confirmatory results of the high level of activity of the docetaxel-cisplatin regimen. Proc Am Soc Clin Oncol 1999;129a.
   Google Scholar
• Bernard A, Antoine EC, Gozy M. Docetaxel and cisplatin in anthracycline-pretreated advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1998;128a.
   Google Scholar
• Vogel CL, Nabholtz JM. Monotherapy of metastatic breast cancer: a review of newer agents. Oncologist 1999;17–33.
   PubMedGoogle Scholar
• Spielmann M, Zelek L, Nabholtz JM, Tonkin K, Aapro MS. Editors, Breast Cancer Management. Application of Evi-dence to Patient Care, Martin-Dunitz, London, 2000.
   Google Scholar
• Hochster H, Wasserheit C, Siddiqui N. Vinorelbine/cis-platin therapy of locally advanced and metastatic breast cancer: an active regimen. Proc Am Soc Clin Oncol 1997: 173a.
   Google Scholar
• Mustacchi G, Muggia M, Milani S, Ceccherini R, Leita ML, Dellach C. A phase II study of cisplatin and vinorelbine in pa-tients with metastatic breast cancer. Ann Oncol 2002;(13): 1730–1736.
   Google Scholar
• Shamseddine Al, Taher A, Dabaja B, Dandashi A, Salem Z, El Saghir NS. Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer. Am J Clin Oncol 1999;298–302.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of an-thracycline- and/or paclitaxel-containing regimens. Cancer 1998;134–140.
   PubMed Web of Science ®Google Scholar
• Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Pateras H, Efremidis AP. Vinorelbine and cisplatin in metasta-tic breast cancer patients previously treated with anthracyclines. Ann Oncol 2000;1155-1160.
   Google Scholar
• Gunel N, Akcali Z, Yamac D, Onuk E, Yilmaz E, Bayram O. Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer. Tumori 2000;283–285.
   PubMed Web of Science ®Google Scholar
• Szatkowska L, Mazurkiewicz M, Brzozowska A. Cisplatin and vinorelbine therapy of previously treated advanced breast cancer (preliminary studies). Pol Merkuriusz Lek 2001; 148-149.
   Google Scholar
• Nolè F, Munzone E, Mandala M, et al. Vinorelbine, cis-platin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study. Ann Oncol 2001; (12): 95-100.
   Google Scholar
• Jones AL, Smith 1E, O'Brien ME, Talbot D, Walsh G, Ra-mage F. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally ad-vanced breast cancer: an active new regimen. J Clin Oncol 1994;1259-1265.
   Google Scholar
• Eisen T, Smith 1E, Johnston S, Ellis PA, Prendiville J, Sey-mour MT. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol 1998;1350-1357.
   Google Scholar
• Peters GJ, Bergman AM, Ruiz van Haperen VW, Veer-man G, Kuiper CM, Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;72–79.
   Google Scholar
• Van Moorsel CJ, Veerman G, Bergman AM, et al. Com-bination chemotherapy studies with gemcitabine. Semin Oncol 1997; S7–23.
   Google Scholar
• Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in pre-viously treated, relapsed breast cancer patients. J Clin Oncol 2000; 2245-2249.
   Google Scholar
• Galvez CA, Galmarini F, Curie M. Monthly cisplatin (C) and gemcitabine (G) as second line chemotherapy for patients with advanced breast cancer. Breast Cancer Res Treat 2000;81.
   Google Scholar
• Heinemann V. Gemcitabine plus cisplatin for the treat-ment of metastatic breast cancer. Clin Breast Cancer 2002;24–29.
   PubMedGoogle Scholar
• Nagourney RA. Gemcitabine plus cisplatin in breast can-cer. Oncology (Huntingt.) 2001;28–33.
   PubMed Web of Science ®Google Scholar
• Burch PA, Mailliard JA, Hillman DW. Phase II study of gemcitabine and cisplatin in patients with metastatic breast can-cer (MBC) and failure on prior chemotherapy: a North Central Cancer Treatment Group trial. Breast Cancer Res Treat 2000;81.
   Google Scholar
• Kolaric K, Vukas D. Carboplatin activity in untreated metastatic breast cancer patients - results of a phase II study. Can-cer Chemother Pharmacol 1991; (27): 409-412.
   Google Scholar
• Carmo-Pereira J, Dittrich C, Keizer J, et al. Phase II trial of carboplatin in carcinoma of the breast. Ann Oncol 1990; (1): 3-33 (abstract).
   Google Scholar
• Martin M, Diaz-Rubio E, Casado A, et al. Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 1992; (10): 433-437.
   Google Scholar
• O'Brien ME, Talbot DC, Smith LE. Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 1993; (11): 2112-2117.
   Google Scholar
• Martin M, Diaz-Rubio E, Casado A, et al. Phase II study of carboplatin in advanced breast cancer: preliminary results. Semin Oncol 1991;(18) (suppl 2): 23-27.
   Google Scholar
• Jodrell DI, Egorin MJ, Canetta RM, et al. Relationship be-tween carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; (10):520-528.
   Google Scholar
• Deheft° F, Durando A, Camanni M, et al. Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study. Eur J Gynaecol Oncol 1997;185–187.
   Google Scholar
• Van der Gaast A, Bontenbal M, Planting AS, Kok TC, Splinter TA. Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancer. Ann Oncol 1994;858–860.
   PubMed Web of Science ®Google Scholar
• Crown J, Hakes T, Reichman B, Lebwohl D, Gilewski T, Surbone A. Phase 11 trial of carboplatin and etoposide in metasta- tic breast cancer. Cancer 1993;1254-1257.
   Google Scholar
• Fountzilas G, Skarlos D, Theoharis D, Giannakakis T, Stathopoulos G. Carboplatin and oral etoposide in the treatment of patients with advanced breast cancer refractory to anthracy-clines. Tumori 1993;389–392.
   PubMed Web of Science ®Google Scholar
• Aguiar LF, Hegg R, Graziane SR. Phase II study of car-boplatin and VP-16 (etoposide) association in first line treatment of advanced breast cancer. Proc Am Soc Clin Oncol 1993;83.
   Google Scholar
• Hugh A, Sappino AP, Anchisi S, et al. Infusional ECarboF in patients with advanced breast cancer: a very active and well-tolerated out-patient regimen” Ann Oncol 2000;1557-1561.
   Google Scholar
• Bonnefoi H, Smith 1E, O'Brien ME, Seymour MT, Powles TJ, Allum WH. Phase II study of continuous infusional 5-fluo-rouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infu-sional ECarboF): a very active and well-tolerated outpatient reg-imen. Br J Cancer 1996;391-396.
   Google Scholar
• Closon MT, Verbeke L, Kains JP, Tijtgat J, Schallier D. Combination chemotherapy with carboplatin, cyclophosphamide and fluorouracil in advanced breast cancer” Anticancer Res 1995;591-595.
   Google Scholar
• Brambilla C, Ferrari L, Passoni P, Bonadonna G. Carbo-platin in combination as first-line therapy in advanced breast can-cer. Cancer Treat Rev 1993;3–9.
   PubMed Web of Science ®Google Scholar
• Crown JP. The platinum agents: a role in breast cancer treatment? Sem Oncol 2001;(28 suppl 3):28-37.
   Google Scholar
• Perez EA, Hillman DW, Stella PJ, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000; (88): 124-131.
   Google Scholar
• Fountzilas G, Athanassiades A, Papadimitriou V, et al. Pa-clitaxel and carboplatin as first-line chemotherapy for advanced breast cancer. Oncology (Huntington) 1998;(12 suppl 1): 45-48.
   Google Scholar
• Loesch D, Robert N, Asmar L, et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002; (20): 3857-3864.
   Google Scholar
• Fountzilas G et al. Paclitaxel and epirubicin versus pacli-taxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer : a phase III study conducted by HECOG. Ann Oncol 2004;(15): 1517–1526.
   Google Scholar
• Brufsky A, Matin K, Cleary D, et al. A phase II study of carboplatin and docetaxel as first line chemotherapy for metasta-tic breast cancer. Proc Am Soc Clin Oncol 2002; 21: 52b.
   Web of Science ®Google Scholar
• Fitch RA, Suman VJ, Mailliard JA et al. N9932: phase II cooperative group trial of docetaxel and carboplatin (CBDCA) as first-line chemotherapy for metastatic breast cancer (MBA). Proc Am Soc Clin Oncol 2003; 22: 23.
   Google Scholar
• Perez EA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist 2004; (9): 518-527.
   Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; (344): 783-792.
   Google Scholar
• Pegram MD, Pienkowski T, Northfelt DW, et al. Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Plat-inum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer. J Nat Cancer Inst 2004; (96): 759-769.
   Google Scholar
• Burris H, Yardley D, Jones S, et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004;(229): 1621–1629.
   Google Scholar
• Robert N, Leyland-Jones B, Asmar I, et al. Randomized Phase III study of trastuzumab, paclitaxel, and carboplatin com-pared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; (24): 2786-2792.
   Google Scholar
• Perez EA, Suman VJ, Rowland KM, et al. Two concur-rent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005; (6): 425-32.
   Google Scholar
• Pegram M, Forbes J, Pienkowski T, et al. On behalf of the BCIRG007 investigators. BCIRG007: first overall survival analysis of randomized phase III trial of trastuzumab plus doc-etaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2007; (25): 34s, abstract LBA1008.
   Google Scholar
• Mathe G, Kidani Y, Triana K, Brienza S, Ribaud P, Gold-schmidt E. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother 1986; 372–376.
   PubMed Web of Science ®Google Scholar
• Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R. Phase I trial of 5-day continuous venous infusion of ox-aliplatin at circadian rhythm-modulated rate compared with con- stant rate. J Natl Cancer Inst 1990;1046-1050.
   Google Scholar
• GandiNistico C, Brienza S, Vaccaro A, D'Ottavio A, Zappala AR. Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 2001; 179–182.
   Google Scholar
• Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chol-let P, Misset JL. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol 2002 ;2551-2558.
   Google Scholar
• Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated ad-vanced breast cancer: a phase II study. Ann Oncol 2003; (14): 537-542.
   Google Scholar
• Thuss-Patience PC, Von Minckwitz G, Kretzschamar A, Loibl S, Schaller G, Dorken B. Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study. Anticancer Drugs 2003; (14): 549-53.
   Google Scholar
• Caruba T, Cottu PH, Madelaine-Chambrin I, Espie M, Misset JL, Gross-Goupil M. Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients. Breast J 2007; (13): 165-71.
   Google Scholar
• Kakolyris S, Kalbakis K, Potamianou A, et al. Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pre-treated patients with metastatic breast cancer: a multicenter phase II study. Oncology 2006; (70): 273-279.
   Google Scholar
• Airoldi M, Cattel L, Passera R, Pedani F, Delprino L, Mi-cari C. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. Am J Clin Oncol 2006; (29): 490-494.
   Google Scholar
• Penault-Llorca FM, Nayl B, Mouret-Reynier M, et al. Gemcitabine oxaliplatin (GEMOX) is an active combination in heavily pretreated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2007; (25): 52s, abstract 1082.
   Google Scholar
• Delozier T, Guastalla JP, Yovine A, et al. A phase II study of an oxaliplatin/vinorelbine/5fluorouracil combination in pa-tients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Anticancer Drugs 2006; (17): 1067-1073.
   Google Scholar
• Petit T, Benider A, Yovine A, et al. Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracy-cline- and taxane-pre-treated metastatic breast cancer. Antican-cancer Drugs 2006; (17): 337-43.
   Google Scholar
• Baur M, Drescher A, Gneist M, Dittrich C, Jaehde U. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction. Cancer Chemother Pharmacol 2007 Mar 30 [Epub ahead of print].
   Google Scholar
• Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 2004; (4): 53-81.
   Google Scholar
• Crown J, Pegram M. Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecu-larly targeted therapy. Breast Cancer Res Treat 2003;(79 suppl 1): S11-S18.
   Google Scholar
• Belani CP. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, genitourinary tu-mors and myeloma. Semin Oncol 2004; (31 suppl. 14): 25-33.
   Google Scholar
• Carrick S, Ghersi D, Wilcken N, Simes J. Platinum con-taining regimens for metastatic breast cancer (Review). The Cochrane Library 2007, Issue 2.
   Google Scholar
• Chia JW, Ang P, See H, et al. Triple-negative metasta-tic/recurrent breast cancer: treatment with paclitaxel/carboplatin combination chemotherapy. Proc Am Soc Clin Oncol 2007; 25: 53s, abstract 1086.
   Google Scholar
• Li HC, Russell CA. Gemcitabine and platinum-based chemotherapy in metastatic breast cancer. Oncology 2004; 18 (suppl 12).
   Google Scholar
• Laessig D, Vehling-Kaiser U, Stemmler HJ, et al. Evalu-ation of gemcitabine plus carboplatin in pretreated, metastatic breast cancer patients: Final analysis of a phase II trial. Proc Am Soc Clin Oncol 2007; 25:50s, abstract 1074.
   Google Scholar
• Ruiz M, Salvador J, Bayo J, et al. Phase-II study of weekly schedule of trastuzumab, paclitaxel and carboplatin followed by a week off every 28 days for HER 2+ metastatic breast cancer. Cancer Chemother Pharmacol 2008; [Epub ahead of print]
   Google Scholar
• Moura GL, Pasquini R, Frare A, Vianna K, Albini L, Padilha S. Gemcitabine and cisplatin in metastatic breast cancer. Proc Am Soc Clin Oncol 2007; 25: 53s, abstract 1084.
   Google Scholar
• Oksuzoglu B, Abali H, Ozdemir N, Budakoglu B, Hayran M, Zengin N. Capecitabine/cisplatin doublet in anthracycline and taxane pre-treated patients with metastatic breast carcinoma. Proc Am Soc Clin Oncol 2007; 25: 55s, abstract 1093.
   Google Scholar
• Xu B, Jiang Z, Kim S, et al. Randomized phase II study of biweekly gemcitabine (gem)-paclitaxel (pac), gem-carboplatin (carb) and gem-cisplatin (cis) as first-line treatments in metastatic breast cancer (MBC) after anthracycline failure. Proc Am Soc Clin Oncol 2007; 25: 56s, abstract 1099.
   Google Scholar
• Peria FM, Zola FE, Tizzi DG, et al. Combination chemotherapy with gencitabine and cisplatin in anthracycline and taxane pretreated metastatic breast cancer. Proc Am Soc Clin Oncol 2007; 25: 59s, abstract 1108.
   Google Scholar
• Leong C,Vidnovic N, DeYoung M et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370–80.
   Google Scholar
• Kong C, Zhu Y, Sun C, et al. Inhibition of tumor angio-genesis during cisplatin chemotherapy for bladder cancer im-proves treatment outcome. Urology 2005; 65: 395–9.
   PubMed Web of Science ®Google Scholar
• Battacharyya A, Ear US, Koller BH et al. The breast can-cer susceptibility gene BRCA1 is required for subnuclear assem-bly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275: 23899–903.
   Google Scholar
• Martin LP, Hamilton TC, Schilder RJ. Platinum resist-ance: the role of DNA repair pathways. Clin Cancer Res 2008; 14: 1291–5.
   PubMed Web of Science ®Google Scholar
• Yde CW, Gyrd-Hansen M, Lykkesfeldt AE et al. Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther 2007; 6: 1869–76
   Google Scholar